Clinical trials - page 7

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to;Assess the Safety and Efficacy of Zipalertinib in Patients;with Locally Advanced or Metastatic Non-Small Cell Lung;Cancer with Exon 20 Insertion and Uncommon/Single or;Compound Epidermal Growth Factor Receptor Mutations.

Randomized, Controlled, Open-label, Phase 3, Global Multi-;Center Trial to Assess the Efficacy and Safety of Zipalertinib;plus Chemotherapy versus Chemotherapy alone, in Patients;with Previously Untreated, Locally Advanced or Metastatic;Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with;Epidermal Growth Factor Receptor (EGFR) Exon 20;Insertion (ex20ins) Mutations.

A randomized non-comparative phase II study of Maintenance therapy with OSE2101 plus FOLFIRI, or FOLFIRI after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic Pancreatic ductal adenocarcinoma (TEDOPaM - D17-01 PRODIGE 63 Study).

A randomized phase I trial in patients with newly-diagnosed, locoregionally advanced, HPV-negative, squamous cell carcinoma of the head and neck (SCCHN);evaluating a mutanome-directed immunotherapy;initiated at completion of primary treatment or at time of recurrence

A BIOMARKER-DIRECTED, TRANSLATIONAL STUDY OF HIGH-THROUGHPUT MOLECULAR PROFILING OF HR+/HER2- METASTATIC BREAST CANCER TREATED WITH ENDOCRINE THERAPY AND RIBOCICLIB.

A Phase III, Open-label, Randomised Study of Osimertinib;With or Without Datopotamab Deruxtecan (Dato-DXd), as;First-line Treatment in Participants With Epidermal Growth;Factor Receptor (EGFR) Mutation-positive, Locally Advanced;or Metastatic Non-small Cell Lung Cancer;(TROPION-Lung14)

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST)

Investigation of Tumour Spectrum, Penetrance and Clinical Utility of Germline Mutations in New Breast and Ovarian Cancer Susceptibility Genes.

Comparative Evaluation of Care Strategies on Dressing Change-induced Bleeding in Patients With Bleeding Malignant Wounds (TUMOSS)

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin;(ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype,;Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.

Elacestrant for Treating ER+/·HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA)

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus;InvestigatorÀs Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC).

A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors.

A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available.